Table 3 Coefficients of regression models associated with diagnostic outcomes, adjusting for age.
Predictor | ASD Diagnosis | ID Diagnosis | FSIQ | ABC |
---|---|---|---|---|
 | OR [95% CI] | OR [95% CI] | B [95% CI] | B [95% CI] |
PCCB gene1 | 0.26 [0.05, 1.18] | 5.50 [1.21, 30.10] | −9.85 [−29.10, 9.40] | −4.12 [−21.49, 13.26] |
Two loss-of-function alleles2 | 3.85 [0.76, 22.83] | NA3 | −19.2 [−38.94, 0.54] | −18.98 [−36.36, −1.6] |
1-13C-Propionate oxidation, 60-min, % (ln) | 0.57 [0.25, 1.18] | 0.04 [ < 0.001, 0.24]4 | 15.72 [9.69, 21.76] | 15.9 [10.89, 20.9] |
Propionylcarnitine, plasma, µmol/L (ln) | 1.88 [0.41, 10.55] | 2203.06 [32.13, 8436433.3] | −30.18 [−43.78, −16.59] | −23.46 [−38.45, −8.46] |
Erythropoietin, serum, mIU/mL (ln) | 28.11 [2.55, 1050.72] | 115.39 [6.82, 10245.56] | −36.77 [−52.62, −20.92] | −25.12 [−43.23, −7.01] |
FGF21, plasma, pg/mL (ln) | 0.79 [0.43, 1.38] | 2.01 [1.1, 4.31] | −8.52 [−15.28, −1.77] | −7.88 [−13.58, −2.18] |
GDF15, plasma, pg/mL (ln) | 1.51 [0.62, 3.99] | 59.83 [6.59, 2743.82] | −22.23 [−30.01, −14.45] | −15.92 [−24.28,−7.57] |
Glutamine, plasma, µmol/L (ln) | 0.07 [0, 0.9] | 0.01 [0, 0.18] | 51.07 [26.09, 76.05] | 31.78 [7.47, 56.1] |
Glutamine, urine, nmol/mg creatinine (ln) | 0.48 [0.1, 2.07] | 0.03 [0, 0.26] | 17.88 [3.75, 32.01] | 11.23 [−5.68, 28.13] |
Glycine, plasma, µmol/L (ln) | 0.85 [0.21, 3.31] | 0.69 [0.17, 2.57] | 5.59 [−12.44, 23.63] | 6.05 [−9.42, 21.52] |
Total 2-methylcitrate, plasma, nmol/L (ln) | 1.36 [0.46, 4.44] | 91.81 [7.41, 7176.88] | −16.11 [−26.26, −5.95] | −11.23 [−23.03, 0.58] |